Skip to main content
. Author manuscript; available in PMC: 2019 Dec 5.
Published in final edited form as: Sci Transl Med. 2019 Jun 5;11(495):eaav5597. doi: 10.1126/scitranslmed.aav5597

Fig. 8. Combination lymphocyte-directed immunomodulation remits pneumonitis in patients with APECED.

Fig. 8.

(A) Number of patients reporting cough at baseline and at 1 and 6 months after treatment initiation (n = 5). (B) Percent residual radiographic abnormalities calculated at 1 and 6 months after treatment initiation relative to the pretreatment radiographic abnormalities (n = 5). Statistical analysis of comparison data was performed by paired t test. (C) Representative coronal chest CT images at baseline and at 1 and 6 months after treatment initiation (patient 2; table S2). (D) 3D reconstructed CT images at baseline and at 1 and 6 months after treatment initiation (patient 5; table S2). (E to H) Pulmonary function assessed by measurements at baseline and after treatment initiation of % oxygen desaturation during the 6-min walk (n = 4) (E), the 6-min walk distance in meters (n = 4) (F), the ratio of forced expiratory volume at 1 s to forced vital capacity (FEV1/FVC) (n = 3) (G), and DLCO (n = 3) (H). (I) Shown is the autoantibody immunoreactivity against BPIFB1 and KCNRG as light units (LU) using the LIPS immunoassay at baseline and at 1 and 6 months after treatment initiation (n = 4).